Which antianginal agent can also improve outcomes in patients with heart failure?

Beta-blockers are the antianginal agents that have been shown to improve outcomes in patients with heart failure. This class of drugs works by blocking the effects of adrenaline on the heart, leading to a reduction in heart rate and blood pressure. By doing so, they help decrease the workload on the heart and improve its efficiency, which is particularly beneficial for individuals suffering from heart failure, as their heart may already be under stress.

In addition to their role in managing angina, beta-blockers have been established as a key component in the treatment of heart failure. Their ability to improve heart function, reduce hospitalizations, and increase survival rates makes them unique among the options presented.

Other antianginal agents, such as calcium channel blockers and nitrates, primarily focus on relieving symptoms of angina rather than directly improving heart failure outcomes. While these agents can help with symptoms, they do not provide the same beneficial effects on long-term survival and reduction of heart failure progression as beta-blockers do. Aspirin, although useful in preventing cardiovascular events, does not have a direct role in managing heart failure or improving outcomes in this patient population.